Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €5.56 EUR
Change Today -0.009 / -0.16%
Volume 0.0
2CX On Other Exchanges
As of 12:43 PM 10/13/15 All times are local (Market data is delayed by at least 15 minutes).

chemocentryx inc (2CX) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/16/15 - €8.39
52 Week Low
12/5/14 - €3.29
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CHEMOCENTRYX INC (2CX)

Related News

No related news articles were found.

chemocentryx inc (2CX) Related Businessweek News

No Related Businessweek News Found

chemocentryx inc (2CX) Details

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of orally administered therapeutics to treat autoimmune diseases, inflammatory disorders, and cancer in the United States. Its drug candidates in clinical development include CCX140 that has completed a Phase II clinical trial for the treatment of patients with diabetic nephropathy, a form of kidney disease; CCX872, an orally administered inhibitor that is under Phase Ib clinical trial for pancreatic cancer; and CCX168, which has completed a Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic anti-body associated renal vasculitis. The company’s drug candidates in clinical development also comprise Vercirnon for the treatment of patients with moderate-to-severe Crohn’s disease; and CCX507 inhibitor, which has completed a Phase I clinical trial for the treatment of inflammatory bowel disease. Its earlier-stage programs in immuno-oncology and autoimmune diseases include CCR6 Inhibitor for autoimmune diseases; CCR4 Inhibitor for atopic autoimmune disorders; CXCR6 Inhibitor for liver diseases; CCR1 Inhibitor for inflammatory diseases and rheumatoid arthritis; and CXCR7 Inhibitor for glioblastoma multiforme. The company was founded in 1997 and is headquartered in Mountain View, California.

58 Employees
Last Reported Date: 03/13/15
Founded in 1997

chemocentryx inc (2CX) Top Compensated Officers

Founder, Chairman, Chief Executive Officer an...
Total Annual Compensation: $550.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $400.0K
Chief Medical Officer
Total Annual Compensation: $384.3K
Compensation as of Fiscal Year 2014.

chemocentryx inc (2CX) Key Developments

ChemoCentryx, Inc. Announces Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

ChemoCentryx, Inc. announced consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company's loss from operations was $12,178,000 compared with $12,384,000 a year ago. Net loss was $12,078,000 or $0.28 per basic and diluted share compared with $12,261,000 or $0.28 per basic and diluted share a year ago. For the six months, the company's loss from operations was $24,287,000 compared with $24,056,000 a year ago. Net loss was $24,084,000 or $0.55 per basic and diluted share compared with $23,798,000 or $0.55 per basic and diluted share a year ago.

ChemoCentryx, Inc. Announces Board Changes

ChemoCentryx, Inc. announced that effective July 28, 2015, Thomas A. Edwards, retired partner of Latham & Watkins, LLP, has been appointed to the Company's Board of Directors. Mr. Edwards will serve as a Class III director until the 2017 annual stockholder's meeting. The Company also announced that effective as of the same date, Ira Klein, MD, MBA, FACP resigned from the Company's Board of Directors. Thomas Edwards has more than three decades of legal experience in the life sciences industry. Prior to his retirement from Latham & Watkins in 2014, Mr. Edwards supported dozens of biopharmaceutical companies in their general legal efforts, capital financings, acquisitions, partnerships and numerous other strategic business and legal initiatives.

ChemoCentryx, Inc. to Report Q2, 2015 Results on Aug 06, 2015

ChemoCentryx, Inc. announced that they will report Q2, 2015 results at 5:00 PM, US Eastern Standard Time on Aug 06, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2CX:GR €5.56 EUR -0.009

2CX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2CX.
View Industry Companies

Industry Analysis


Industry Average

Valuation 2CX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHEMOCENTRYX INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at